Preliminary Scientific Programme

June 7-8-9, 2020

Preparing nephrology for the future Towards sustainable nephrology care

PLENARY LECTURES

1) Sustainable healthcare Nicholas Watts, London, United Kingdom

2) AKI, CKD and cancer: the costs of kidney repair Paola Romagnani, Florence, Italy

3) Chronic Kidney Disease: two decades of progress and challenges for the future Andrew Levey, Boston, MS, USA

4) Circadian control of metabolism and inflammation and pathological consequences of clock perturbations
Bart Staels, Lille, France

MINI LECTURES

• Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era
• Global challenges in end-stage kidney disease treatment
• ERBP hyperkalaemia guideline. Tools for clinical practice
• Genetic studies of CAKUT
• Learning from genetic testing in kidney disease: expanding phenotypes
• Using proteomics to define the molecular landscape of cell matrix adhesion in the glomerulus
• Proteinuria reduction, slope in GFR as surrogate end point in trials in nephrology
• Membranous nephropathy: biopsy or not?
• C3 glomerulopathy and aHUS. Are these two different entities or a continuum?
• Should I change my daily practice in the treatment of lupus nephritis with new drugs of SLE?
• Podocyte pathology in nephropathy – new opportunities
• What will nephrology look like in 10 years?
• The changing scenario of the Nephrology workforce
• Compliance with drug treatment in CKD and in hypertension
• Therapeutic inhibition of VEGF signalling and associated nephrotoxicities
• Management and treatment of glomerular diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

• New perspectives in the development of antifibrotic drugs for chronic kidney disease
• A proteomics approach to identify the molecular determinants of hypertension
• Blood pressure in CKD. The KDIGO 2019 standpoint
• From human embryonic nephron stem cells to mature kidney tissue and regeneration
• Anaemia in CKD. The 2019 KDIGO standpoint
• Benefits and barriers and desired outcomes with exercise in patients with ESKD
• Effect of different dialysis techniques on food intake, nutritional status and body stores
• Towards developing a new PD fluid to preserve the peritoneal membrane?
• Multimolecular approaches: increase in diagnosis accuracy or increase in graft cost?
• Is living kidney donation harmless? Advise to the general nephrologist
• High mountain medicine
• Treatment of dyslipidaemia in CKD: where do we stand now?
• Sirtuins in diabetic nephropathy
• Molecular treatment strategies for AKI – a look into the crystal ball

SYMPOSIA

SPECIAL SYMPOSIA

ERA-EDTA Registry

Late Breaking Clinical Trials

Nephrology Pearls (special closing session) ASN Highlights

Combatting kidney disease in Europe: role of European Kidney Health Alliance (EKHA)

1. European Kidney Health Alliance (EKHA): influencing European kidney policy

2. The road towards a European kidney research agenda

3. Differences in European renal replacement (EDITH): measurement brings knowledge

Medicine in the digital age

1. Benchmarking process for artificial intel in health. FG-AI4H

2. How can ubiquitous availability of data help to advance knowledge. Exposome research.

3. Medical apps: do they work? A healthcare provider’s perspective

Click to view content

Track 1 - FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

Electrolytes and acid-base for the future

1. Acid base balance in kidney disease
2. Urinary electrolytes in the clinic: a still unexploited instrument
3. Do SGLT2 inhibitors protect the proximal tubular cells?

Track 2 - HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

Paediatric nephrology

1. Access for paediatric dialysis, and ESPN guidelines
2. Fluid management in paediatric dialysis patients
3. Preserving the peritoneal membrane 4. Intensified dialysis for children – learning from adult studies

ADPKD – tolvaptan and beyond

1. Real world experience of tolvaptan – a global perspective
2. Whole genome sequencing for molecular diagnostics –when is it necessary?
3. Do we need new biomarkers in addition to Total Kidney Volume? Emerging concepts and therapeutic perspectives

Novel diagnostics and treatments for inherited kidney diseases

1. Orphan drugs: from bench to bedside
2. The role of Induced pluripotent stem cells in CKD
3. The use of next generation sequencing for the diagnosis of unsuspected genetic kidney diseases

Genetics in kidney disease

1. Pathophysiological insights in CKD through GWAS: CKDGen
2. Implementation of next-generation sequencing in diagnostic process of the adult CKD patient
3. Autosomal dominant tubulointerstitial kidney disease
4. Large scale genomic-wide association studies in IgA nephropathy in various ethnicities

Track 3 - GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

Big data and artificial intelligence in renal care

1. Acute kidney injury alerting – the UK experience
2. Renal pathology and artificial intelligence
3. Big data and development and evaluation of dialysis care

Advanced renal MRI – the non-invasive renal biopsy in 2020

1. Renal MRI application in research and in clinical practice
2. Renal MRI to detect tissue perfusion, oxygenation, inflammation and fibrosis
3. MRI: renal blood flow, the GFR and renal metabolism

Systemic diseases and the kidney

1. Recent challenges in amyloidosis treatment
2. Advancements in IGA disease
3. The kidney in SLE: an update
4. Addressing the challenges posed by pregnancy in CKD

Novel tools and target in renal fibrosis

1. CRISPR/Cas9 to attenuate renal fibrosis
2. Single-cell RNA sequencing in renal fibrosis
3. Virus-induced interstitial fibrosis – from mice to men

New immune therapies and onco-nephrology

1. New immune therapies and their mechanism
2. Recent and forthcoming treatments of membranous nephropathy
3. Are immune therapies allowed in kidney transplant?
4. What should the nephrologist know about onco-nephrology for everyday practice?

Track 4 - CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

CKD – PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

Anaemia treatment in CKD: a changing scenario

1. Erythropoietin Stimulating Agents (ESAs) after thirty years: are there differences among ESAs?
2. High-dose proactive intravenous iron treatment in ESKD patients
3. Hypoxia-inducible factor prolyl hydroxylase inhibitors. Safer than ESAs?

Refocussing clinical research in CKD

1. The unique complexity of the clinical presentation of patients seen by nephrologists
2. Identifying and addressing symptoms most burdensome to persons with advanced CKD
3. Smoothing the transition to ESKD to improve early dialysis outcomes

Cognitive impairment in CKD

1. Progress in the understanding of cognitive problems in human diseases, from biomarkers to brain imaging
2. Cognitive impairment in CKD patients: the dimension of the problem
3. Organic brain damage in CKD patients

The diversified world of nephrology: what the nephrologists do and how renal care is organised in different countries

1. Nephrology organisation in the USA and Canada
2. The scenario of renal care in Asia and in Australia-New Zealand
3. Kidney care in Europe

Ageing kidney and its implications

1. Mechanisms of kidney ageing: methods for understanding senescence
2. Role of frailty assessments in aged ESKD patients
3. “Prepare for Kidney Care” Study: responsive management vs renal dialysis in advanced chronic kidney disease

Mechanisms on CKD progression

1. Glomerular hyperfiltration: relevant in the clinical scenario?
2. Relevance of dietary factors for CKD progression: focus on potassium, phosphate and magnesium
3. Ischaemic insults and CKD progression

Environmental threats to kidney health

1. Particulate matter, nitrogen dioxide and carbon monoxide with the risk of kidney disease
2. Chronic kidney disease of unknown aetiology: population-level detection strategies
3. CKD in agricultural communities

Track 5 - END-STAGE KIDNEY DISEASE, HAEMODIALYSIS

END-STAGE KIDNEY DISEASE, HAEMODIALYSIS

Dietary approaches in CKD: promoting quality over quantify

1. Can we liberalize the diet of patients on haemodialysis?
2. Interventions targeting serum phosphate to improve clinical outcomes in CKD: doable? Useful?
3. Personalizing the diet of end-stage kidney disease with transition to dialysis

Wasting in CKD: targeting the muscle

1. Wasting and malnutrition in the elderly, what do we need to take care of?
2. Reconciling geriatric and nephrology nutritional views in the elderly patient with CKD
3. Preserving and recovering skeletal muscle in CKD patients: the clinical nutrition perspective
4. Preserving and recovering skeletal muscle in CKD patients: novel mechanisms and upcoming therapies

The uraemic toxins saga

1. Uraemic toxins in end-stage kidney disease in 2020: clinically relevant or not?
2. The intestinal microbiota and uraemic solutes accumulation
3. Modification of uraemic toxins by nutrition, dialysis and drug therapy

Pathways to arterial damage and calcification in CKD

1. The multidimension scenario leading to arterial damage in CKD
2. Vitamin K: a special pathway conducive to arterial disease
3. Coronary calcification: disease-severity marker or causal risk factor?
4. New paradigms in the pathogenesis and progression of the renal osteodystrophy

Green health care in practice

1. Environmental impact of dialysis and how to reduce it
2. Towards carbon neutral hospital care
3. Adapting green targets in the healthcare system

Expanding the patient’s voice in nephrology with patient outcome measures

1. Aligning research with patient priorities: a SONG for harmonizing outcomes in trials
2. Expectations and hopes of a patient entering a chronic dialysis programme
3. Patient story
4. Debate and interaction with the audience

Everyday issues during haemodialysis

1. Assessment of dry weight in 2020
2. Organ ischaemia during HD: occurrence and prevention
3. Pruritus, restless legs, acidosis and insomnia: should we care more?

Track 6 - HOME THERAPIES, PERITONEAL DIALYSIS

HOME THERAPIES, PERITONEAL DIALYSIS

Towards more home and self-care

1. Current status of small dialysis machines: pros and cons
2. Journey towards a wearable or transportable dialysis machine
3. Home dialysis and the use of new technologies

PD strategies and outcomes

1. Optimal peritoneal dialysis access in 2020
2. Incremental peritoneal dialysis
3. How to stimulate PD programmes

Track 7 - TRANSPLANTATION AND IMMUNOLOGY

TRANSPLANTATION AND IMMUNOLOGY

How to manage maintenance anti-rejection treatment in the presence of relevant co-morbidities?

1 Severe infections
2. Solid cancer
3. PTLD

Newer outcomes and strategies for implementing clinical trials in kidney transplantation

1. Non-invasive biomarkers of rejection
2. Molecular biopsy
3. Patient reported outcomes
4. Planning RCTs across different EU Countries: opportunities and threats

Track 8 - HYPERTENSION, DIABETES, VASCULAR DISEASES

HYPERTENSION, DIABETES, VASCULAR DISEASES

The inflammatory pathway in CKD: treatments at last?

1. The canonical Wnt/ß-catenin signalling pathway is critical for kidney damage
2. Inflammasome-IL-1α/IL-ß-IL-1receptor system blockade as a target in experimental models and in CKD patients
3. Circulating bacterial fragments as cardiovascular risk factors in CKD

Sympathetic overactivity as a major trigger of cardiovascular and renal outcomes in CKD

1. Sympathetic activity in CKD: high to detect, relevance and treatment
2. Renal denervation: where do we stand and what is the relevance to the nephrologist?
3. NPY signals a high risk for CKD progression and cardiovascular complications in CKD: a gut microbiome – nervous system connection?

Cardiovascular and renal protection – effects of SGLT2 inhibitors and GLP-1 receptor agonists in people with CKD and type 2 diabetes

1. Clinical outcome with new agents in DM 2
2. What are the specific effects of SGLT2-I?
3. What are the specific effects of GLP-1 RA?

The hypertension spectrum in CKD: pathophysiology and risk

1. Dissecting the role of hypertension in the high-risk scenario of CKD
2. New insights in the role of sodium in CKD
3. Measurements of arterial stiffness in CKD: better than BP metrics?

Track 9 - ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY

ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY

The AKI – AKD – CKD continuum

1. Global epidemiology and outcomes of AKI with respect to CKD
2. e-Alert and AKI detection: does it work?
3. The clinical continuum of AKI – AKD – CKD: what should we look for?

Current aspects of AKI prevention and treatment

1. Cost-effective prevention strategies for AKI
2. Nutrition in patients with AKI: does it matter?
3. RRT – when to start and what to choose?